2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.
Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.
It will be interesting to see if, at some point in time, that gynecologic cancers such as vulvar cancer and cervical cancer will instead be classified by their driver mutations. By doing this, patients with vulvar cancer, for example, could enroll on basket trials with patients who have other tumor types, Chase explains. This is being explored, but only in phase I studies, she adds.
Eventually, patients will undergo a biopsy for their gynecologic malignancy, and researchers will determine how it works and find a drug to target it.